Empowered Patient Podcast

Michael Boerner is the Founder and CEO of Engage Technologies Group, which uses short-form videos to educate and motivate patients. It might be for someone with a diagnosed disease or a surgical process where it's a need for pre-operative or post-operative information. Their mobile intelligence platform is designed to deliver content to patients at the moment when it makes the most sense on their preferred screen.

Michael explains, "So when we transform lives by delivering wisdom, it's in the format of short-form video. What we find is people love video, they just don't want it to be long. So, we found that the best way to be able to educate someone is with kind of the three biggest consumer behavioral shifts."

"But short-form video, what's tough about brief videos, about 90 seconds, is you can't really talk about anything super complex in 90 seconds, but you can if you put the videos together in what we call an arc or an arc of engagement, a sequence of video content. That allows someone to be able to tap next and go to the next key kind of chapter in that educational journey."

#DigitalHealth #MobileHealth #PatientEducation #PatientEngagment #PatientRelationships #ShortFormVideo

engagetg.com

Listen to the podcast here

Michael Boerner is the Founder and CEO of Engage Technologies Group, which uses short-form videos to educate and motivate patients. It might be for someone with a diagnosed disease or a surgical process where it's a need for pre-operative or post-operative information. Their mobile intelligence platform is designed to deliver content to patients at the moment when it makes the most sense on their preferred screen.

Michael explains, "So when we transform lives by delivering wisdom, it's in the format of short-form video. What we find is people love video, they just don't want it to be long. So, we found that the best way to be able to educate someone is with kind of the three biggest consumer behavioral shifts."

"But short-form video, what's tough about brief videos, about 90 seconds, is you can't really talk about anything super complex in 90 seconds, but you can if you put the videos together in what we call an arc or an arc of engagement, a sequence of video content. That allows someone to be able to tap next and go to the next key kind of chapter in that educational journey."

#DigitalHealth #MobileHealth #PatientEducation #PatientEngagment #PatientRelationships #ShortFormVideo

engagetg.com

Download the transcript here

Dr. Sameer Berry is the Chief Medical Officer of Oshi Health, and he shines a light on the challenges patients face from gastrointestinal conditions and the lack of effective treatments available from doctors for GI-related symptoms. While the reimbursement and payment model discourages a team approach to treating these patients, Oshi Health is taking a multidisciplinary integrated healthcare approach with a focus on the enteric nervous system.

Sameer explains, "Where this comes from is the understanding that anatomically, there's actually an entirely separate nervous system that exists in the GI tract, and it's called the enteric nervous system. So, these are nerve cells, the same types of nerve cells that are in your spinal cord, in your brain, those nerve cells are in your gut. And just like the nerves in your brain respond to environmental stressors that might cause you to feel anxious, depressed, sad, happy, these nerves that are in your gut can respond to environmental stressors. But instead of causing you to feel anxious or depressed, they can cause GI symptoms."

"I don't see the use of drugs diminishing. I see us refining the molecular targets for the future of pharmacology and functional GI conditions. Where those drugs target, I think, will start to incorporate our understanding of the enteric nervous system and the interplay of the enteric nervous system with both the parasympathetic and the sympathetic nervous system."

@OshiHealth #GITwitter #MedTwitter #GI #IBS #GutHealth #MindGut #EntericNervousSystem

OshiHealth.com

Listen to the podcast here

Dr. Sameer Berry is the Chief Medical Officer of Oshi Health, and he shines a light on the challenges patients face from gastrointestinal conditions and the lack of effective treatments available from doctors for GI-related symptoms. While the reimbursement and payment model discourages a team approach to treating these patients, Oshi Health is taking a multidisciplinary integrated healthcare approach with a focus on the enteric nervous system.

Sameer explains, "Where this comes from is the understanding that anatomically, there's actually an entirely separate nervous system that exists in the GI tract, and it's called the enteric nervous system. So, these are nerve cells, the same types of nerve cells that are in your spinal cord, in your brain, those nerve cells are in your gut. And just like the nerves in your brain respond to environmental stressors that might cause you to feel anxious, depressed, sad, happy, these nerves that are in your gut can respond to environmental stressors. But instead of causing you to feel anxious or depressed, they can cause GI symptoms."

"I don't see the use of drugs diminishing. I see us refining the molecular targets for the future of pharmacology and functional GI conditions. Where those drugs target, I think, will start to incorporate our understanding of the enteric nervous system and the interplay of the enteric nervous system with both the parasympathetic and the sympathetic nervous system."

@OshiHealth #GITwitter #MedTwitter #GI #IBS #GutHealth #MindGut #EntericNervousSystem

OshiHealth.com

Download the transcript here

Dr. Jacob Hascalovici is the Co-Founder and Chief Medical Officer of Clearing which is in the business of transforming chronic pain care. While some chronic pain has no cure, there are many strategies that can be used to manage the symptoms and improve the quality of life of a patient. One of the key goals of Clearing is to leverage the use of technology to help remove obstacles in the chronic pain care environment.

Jacob explains, "When we think about individual treatments in isolation, we call that unimodal care. I'd say that on an individual basis, the effectiveness of a treatment is limited. I rarely see patients with chronic pain who have a 100% response to a single therapy. But when we employ multimodal therapies where we have home exercise or physical therapy, plus a topical, plus an oral, plus an injection, that's when we start to see a very effective treatment strategy and plan."

"Pain is a very personal experience. It's highly subjective, it's deeply personal, and there is a multitude of factors that can affect our perception of pain. In order for us to manage something that is so personal and so subjective, we really need to consider all of the biological factors, the psychological factors, and the social factors that affect an individual to design a treatment plan that's best for them. We call this the biopsychosocial model for chronic pain care, and that is at the foundation of what we do at Clearing. Highly personalized therapies that focus on the mind, the body, and the social wellbeing of an individual who's suffering from pain."

#ChronicPain #PainTreatment #PainCare #Opioids #NonOpioidTreatment #NociplasticPain #DigitalHealth

clearing.com

Listen to the podcast here

Dr. Jacob Hascalovici is the Co-Founder and Chief Medical Officer of Clearing which is in the business of transforming chronic pain care. While some chronic pain has no cure, there are many strategies that can be used to manage the symptoms and improve the quality of life of a patient. One of the key goals of Clearing is to leverage the use of technology to help remove obstacles in the chronic pain care environment.

Jacob explains, "When we think about individual treatments in isolation, we call that unimodal care. I'd say that on an individual basis, the effectiveness of a treatment is limited. I rarely see patients with chronic pain who have a 100% response to a single therapy. But when we employ multimodal therapies where we have home exercise or physical therapy, plus a topical, plus an oral, plus an injection, that's when we start to see a very effective treatment strategy and plan."

"Pain is a very personal experience. It's highly subjective, it's deeply personal, and there is a multitude of factors that can affect our perception of pain. In order for us to manage something that is so personal and so subjective, we really need to consider all of the biological factors, the psychological factors, and the social factors that affect an individual to design a treatment plan that's best for them. We call this the biopsychosocial model for chronic pain care, and that is at the foundation of what we do at Clearing. Highly personalized therapies that focus on the mind, the body, and the social wellbeing of an individual who's suffering from pain."

#ChronicPain #PainTreatment #PainCare #Opioids #NonOpioidTreatment #NociplasticPain #DigitalHealth

clearing.com

Download the transcript here

Sam Lee, interim Co-CEO and President, and Jim Martin, interim Co-CEO and CFO of Cocrystal Pharma. They're a clinical stage biotech company using their proprietary drug development platform to create novel antiviral therapeutics to treat seasonal influenza and pandemic viral infections like COVID-19.

Jim explains, "There are vaccines, and then there are therapeutics. We are a therapeutic company. We don't produce vaccines. Vaccines are more preventative. What we do is, once you get the illness, we stop the illness through our compounds. So as a therapeutic, you do need that one-two punch of both vaccines and therapeutics. And in the case of influenza, we have every year people getting vaccines, which are good. But the therapeutics that are necessary are far and few between."

Sam elaborates, "So our compounds, the compound IDs of CC-42344, we're currently doing phase one study in Australia, this compound has an outstanding drug-resistant profile. We have not been able to isolate the drug-resistance strains from in vitro test-tube experiments. So we believe this compound is really designed for the pandemic as well as a seasonal treatment, particularly targeting for influenza A infection. And also, because of the excellent drug resistance profile, we believe this would be a real breakthrough influenza treatment for pandemic as well as seasonal infection."

@CocrystalPharma #Flu #Influenza #Pandemic #SeasonalFlu #COVID #Vaccines #COVIDTreatments #FluTreatments

cocrystalpharma.com

Listen to the podcast here

Sam Lee, interim Co-CEO and President, and Jim Martin, interim Co-CEO and CFO of Cocrystal Pharma. They're a clinical stage biotech company using their proprietary drug development platform to create novel antiviral therapeutics to treat seasonal influenza and pandemic viral infections like COVID-19.

Jim explains, "There are vaccines, and then there are therapeutics. We are a therapeutic company. We don't produce vaccines. Vaccines are more preventative. What we do is, once you get the illness, we stop the illness through our compounds. So as a therapeutic, you do need that one-two punch of both vaccines and therapeutics. And in the case of influenza, we have every year people getting vaccines, which are good. But the therapeutics that are necessary are far and few between."

Sam elaborates, "So our compounds, the compound IDs of CC-42344, we're currently doing phase one study in Australia, this compound has an outstanding drug-resistant profile. We have not been able to isolate the drug-resistance strains from in vitro test-tube experiments. So we believe this compound is really designed for the pandemic as well as a seasonal treatment, particularly targeting for influenza A infection. And also, because of the excellent drug resistance profile, we believe this would be a real breakthrough influenza treatment for pandemic as well as seasonal infection."

@CocrystalPharma #Flu #Influenza #Pandemic #SeasonalFlu #COVID #Vaccines #COVIDTreatments #FluTreatments

cocrystalpharma.com

Download the transcript here

Brian Culley is the CEO of Lineage Cell Therapeutics which is developing cell therapy for Dry AMD, a common condition and one of the leading causes of blindness, and to restore the functional capacity of hearing and the spine.

Brian explains, "Conceptually, what we're doing is manufacturing the type of cell that has been lost due to aging or disease or trauma, and in doing so, in transplanting those cells, we're looking to restore function. This is what we saw in the setting of the eye, and this is what we're looking to replicate in the setting of the ear."

"Lineage has a fundamental technology that allows us to manufacture these specific cell types. That technology is capable of manufacturing not just auditory neurons and retinal cells, as we talked about today, but we also can manufacture the cells of your spinal cord. We have treated 25 people who suffered a traumatic spinal cord injury, and we are working to replace those cells so that they can regain function, operate their own wheelchair, dress, and feed themselves."

"Everything gets converted, and so we're able to come up with these largely pure populations of specific cell types. We can do it at a meaningful scale. Meaningful meaning you can actually get into a clinical trial and test to see if they work. The hallmark of our technology is being able to manufacture these cells in a way that the FDA expects. Rather than an academic science experiment, we're really trying to think about these as products that are going to reach patients and be used by surgeons and physicians."

@ceo_culley @lineagecell #LineageCellTherapeutics #Biotech #CellTherapy #CellTransplant #RegenerativeMedicine #ReplaceandRestore

lineagecell.com

Listen to the podcast here

Brian Culley is the CEO of Lineage Cell Therapeutics which is developing cell therapy for Dry AMD, a common condition and one of the leading causes of blindness, and to restore the functional capacity of hearing and the spine.

Brian explains, "Conceptually, what we're doing is manufacturing the type of cell that has been lost due to aging or disease or trauma, and in doing so, in transplanting those cells, we're looking to restore function. This is what we saw in the setting of the eye, and this is what we're looking to replicate in the setting of the ear."

"Lineage has a fundamental technology that allows us to manufacture these specific cell types. That technology is capable of manufacturing not just auditory neurons and retinal cells, as we talked about today, but we also can manufacture the cells of your spinal cord. We have treated 25 people who suffered a traumatic spinal cord injury, and we are working to replace those cells so that they can regain function, operate their own wheelchair, dress, and feed themselves."

"Everything gets converted, and so we're able to come up with these largely pure populations of specific cell types. We can do it at a meaningful scale. Meaningful meaning you can actually get into a clinical trial and test to see if they work. The hallmark of our technology is being able to manufacture these cells in a way that the FDA expects. Rather than an academic science experiment, we're really trying to think about these as products that are going to reach patients and be used by surgeons and physicians."

@ceo_culley @lineagecell #LineageCellTherapeutics #Biotech #CellTherapy #CellTransplant #RegenerativeMedicine #ReplaceandRestore

lineagecell.com

Download the transcript here